Understanding the pathophysiology of severe asthma to generate new therapeutic opportunities.

[1]  C. Baena-Cagnani,et al.  Asthma mortality, inhaled steroids, and changing asthma therapy in Argentina (1990-1999). , 2006, Respiratory medicine.

[2]  H. Bibi,et al.  Do current treatment protocols adequately prevent airway remodeling in children with mild intermittent asthma? , 2006, Respiratory medicine.

[3]  I. Pavord,et al.  Evidence of a role of tumor necrosis factor alpha in refractory asthma. , 2006, The New England journal of medicine.

[4]  J. Vonk,et al.  Predicting adult asthma in childhood , 2006, Current opinion in pulmonary medicine.

[5]  C. Colás,et al.  Effect of Omalizumab on Adenosine 5′-Monophosphate Responsiveness in Subjects with Allergic Asthma , 2006, International Archives of Allergy and Immunology.

[6]  J. Siddiqui,et al.  Anti‐tumor necrosis factor‐α antibody treatment reduces pulmonary inflammation and methacholine hyper‐responsiveness in a murine asthma model induced by house dust , 2006, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[7]  F. Martinez.  Safety of long-acting beta-agonists--an urgent need to clear the air. , 2005, The New England journal of medicine.

[8]  P. Howarth,et al.  Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. , 2005, Thorax.

[9]  D. Wakefield,et al.  Risk factors for asthma and asthma severity in nonurban children in Connecticut. , 2005, Chest.

[10]  D. Postma,et al.  Lung function decline in asthma: association with inhaled corticosteroids, smoking and sex , 2005, Thorax.

[11]  Stefano Guerra,et al.  Outcome of asthma and wheezing in the first 6 years of life: follow-up through adolescence. , 2005, American journal of respiratory and critical care medicine.

[12]  Q. Hamid,et al.  Evidence of remodeling in peripheral airways of patients with mild to moderate asthma: effect of hydrofluoroalkane-flunisolide. , 2005, The Journal of allergy and clinical immunology.

[13]  S. Holgate,et al.  ADAM33: a newly identified gene in the pathogenesis of asthma. , 2005, Immunology and allergy clinics of North America.

[14]  C. Janson,et al.  Are the Asthma Guideline Goals Achieved in Daily Practice? A Population-Based Study on Treatment Adequacy and the Control of Asthma , 2005, International Archives of Allergy and Immunology.

[15]  I. Tillie‐Leblond,et al.  High-resolution computed tomography scan and airway remodeling in children with severe asthma. , 2005, The Journal of allergy and clinical immunology.

[16]  G. Currie,et al.  Long-acting bronchodilator or leukotriene modifier as add-on therapy to inhaled corticosteroids in persistent asthma? , 2005, Chest.

[17]  M. Rosenthal,et al.  Tumour necrosis factor gene polymorphisms and childhood wheezing , 2005, European Respiratory Journal.

[18]  P. Sterk,et al.  Bronchial CD8 cell infiltrate and lung function decline in asthma. , 2005, American journal of respiratory and critical care medicine.

[19]  Judith M. White,et al.  Selective modulation of integrin-mediated cell migration by distinct ADAM family members. , 2005, Molecular biology of the cell.

[20]  B. Harrison,et al.  Difficult asthma in adults: recognition and approaches to management , 2005, Internal medicine journal.

[21]  R. Scott,et al.  Differential proteolytic enzyme activity in eosinophilic and neutrophilic asthma. , 2005, American journal of respiratory and critical care medicine.

[22]  Q. Hamid,et al.  Role of airway smooth muscle in airway remodeling. , 2005, The Journal of allergy and clinical immunology.

[23]  M. Stylianou,et al.  Effect of tumor necrosis factor antagonism on allergen-mediated asthmatic airway inflammation. , 2005, Respiratory medicine.

[24]  G. Walsh.  Novel therapies for asthma--advances and problems. , 2005, Current pharmaceutical design.

[25]  V. Siroux,et al.  Asthma severity and exposure to occupational asthmogens. , 2005, American journal of respiratory and critical care medicine.

[26]  D. Postma,et al.  A disintegrin and metalloprotease 33 polymorphisms and lung function decline in the general population. , 2005 .

[27]  S. Holgate.  The Quintiles Prize Lecture 2004: The identification of the adenosine A2B receptor as a novel therapeutic target in asthma , 2005, British journal of pharmacology.

[28]  A. Burks,et al.  Omalizumab : other indications and unanswered questions. , 2005, Clinical reviews in allergy & immunology.

[29]  D. Duffy,et al.  A novel tissue inhibitor of metalloproteinase-1 (TIMP-1) polymorphism associated with asthma in Australian women , 2005, Thorax.

[30]  S. Wenzel,et al.  Severe asthma in adults. , 2005, American journal of respiratory and critical care medicine.

[31]  A. Woodcock,et al.  Polymorphisms in a disintegrin and metalloprotease 33 (ADAM33) predict impaired early-life lung function. , 2005, American journal of respiratory and critical care medicine.

[32]  I. Adcock,et al.  Decreased histone deacetylase activity in chronic obstructive pulmonary disease. , 2005, The New England journal of medicine.

[33]  J. Ioannidis,et al.  Meta-analysis of the association of beta2-adrenergic receptor polymorphisms with asthma phenotypes. , 2005, The Journal of allergy and clinical immunology.

[34]  David I. Wilson,et al.  ADAM33 expression in asthmatic airways and human embryonic lungs. , 2005, American journal of respiratory and critical care medicine.

[35]  S. Holgate,et al.  Epithelial stress and structural remodelling in childhood asthma , 2005, Thorax.

[36]  J. Bousquet,et al.  Anti‐immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti‐inflammatory activity and clinical efficacy , 2005, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[37]  T. Haahtela,et al.  Airway remodeling and inflammation in symptomatic infants with reversible airflow obstruction. , 2005, American journal of respiratory and critical care medicine.

[38]  I. Hall,et al.  Contribution of ADAM33 polymorphisms to the population risk of asthma , 2005, Thorax.

[39]  J. Bousquet,et al.  The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. , 2005, The Journal of allergy and clinical immunology.

[40]  J Bousquet,et al.  Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE , 2005, Allergy.

[41]  Lance C Bridges,et al.  ADAM-Integrin Interactions: potential integrin regulated ectodomain shedding activity. , 2005, Current pharmaceutical design.

[42]  Jun Zou,et al.  ADAM33 enzyme properties and substrate specificity. , 2005, Biochemistry.

[43]  K. Chung,et al.  Increase in airway neutrophils after oral but not inhaled corticosteroid therapy in mild asthma. , 2005, Respiratory medicine.

[44]  J. Warner,et al.  Markers of eosinophilic inflammation and tissue re‐modelling in children before clinically diagnosed bronchial asthma , 2005, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[45]  D. Price,et al.  The national montelukast survey. , 2005, The Journal of allergy and clinical immunology.

[46]  E. Rönmark,et al.  Different Labelling of Obstructive Airway Diseases in Estonia, Finland, and Sweden , 2005, European Journal of Epidemiology.

[47]  D. Hyde,et al.  Smooth muscle hypertrophy in distal airways of sensitized infant rhesus monkeys exposed to house dust mite allergen , 2004, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[48]  A. Bush,et al.  Airway inflammation in children with difficult asthma: relationships with airflow limitation and persistent symptoms , 2004, Thorax.

[49]  Stephen T Holgate,et al.  Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. , 2004, American journal of respiratory and critical care medicine.

[50]  I. Adcock,et al.  Histone acetylase and deacetylase activity in alveolar macrophages and blood mononocytes in asthma. , 2004, American journal of respiratory and critical care medicine.

[51]  P. Barnes,et al.  Parameters associated with persistent airflow obstruction in chronic severe asthma , 2004, European Respiratory Journal.

[52]  P. Woodruff,et al.  Hyperplasia of smooth muscle in mild to moderate asthma without changes in cell size or gene expression. , 2004, American journal of respiratory and critical care medicine.

[53]  C. Bucca,et al.  Asthma severity and medical resource utilisation , 2004, European Respiratory Journal.

[54]  L. Palmer,et al.  The relationship between infant airway function, childhood airway responsiveness, and asthma. , 2004, American journal of respiratory and critical care medicine.

[55]  Maree H. Poniris,et al.  Extracellular matrix proteins modulate asthmatic airway smooth muscle cell proliferation via an autocrine mechanism. , 2004, The Journal of allergy and clinical immunology.

[56]  J. Bousquet,et al.  Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. , 2004, Chest.

[57]  Jun Zou,et al.  Catalytic Activity of Human ADAM33* , 2004, Journal of Biological Chemistry.

[58]  C. Walker,et al.  Induction of TNF-α Autoantibody Production by AutoVac TNF106: A Novel Therapeutic Approach for the Treatment of Allergic Diseases , 2004, International Archives of Allergy and Immunology.

[59]  S. Holgate,et al.  The splicing and fate of ADAM33 transcripts in primary human airways fibroblasts. , 2004, American journal of respiratory cell and molecular biology.

[60]  L. Palmer,et al.  Transforming growth factor-beta1 promoter polymorphism C-509T is associated with asthma. , 2004, American journal of respiratory and critical care medicine.

[61]  Jun Zou,et al.  Crystal structure of the catalytic domain of human ADAM33. , 2004, Journal of molecular biology.

[62]  P. Barnes.  Corticosteroid resistance in airway disease. , 2004, Proceedings of the American Thoracic Society.

[63]  P. Jeffery.  Remodeling and inflammation of bronchi in asthma and chronic obstructive pulmonary disease. , 2004, Proceedings of the American Thoracic Society.

[64]  I. Adcock,et al.  Combination Therapy of Long-Acting β2-Adrenoceptor Agonists and Corticosteroids for Asthma , 2004, Treatments in respiratory medicine.

[65]  M. Mishima,et al.  Relationship of airway wall thickness to airway sensitivity and airway reactivity in asthma. , 2003, American journal of respiratory and critical care medicine.

[66]  Phil A. Silva,et al.  A longitudinal, population-based, cohort study of childhood asthma followed to adulthood. , 2003, The New England journal of medicine.

[67]  M. Feldmann,et al.  TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases , 2003, Nature Medicine.

[68]  J. Fredberg,et al.  Remodeling of the airway smooth muscle cell: are we built of glass? , 2003, Respiratory Physiology & Neurobiology.

[69]  D. Postma,et al.  The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma , 2003, European Respiratory Journal.

[70]  P. Macklem,et al.  Airway wall remodeling: friend or foe? , 2003, Journal of applied physiology.

[71]  L. Boulet,et al.  Airway remodeling-associated mediators in moderate to severe asthma: effect of steroids on TGF-beta, IL-11, IL-17, and type I and type III collagen expression. , 2003, The Journal of allergy and clinical immunology.

[72]  Jun Zou,et al.  Human ADAM33 messenger RNA expression profile and post-transcriptional regulation. , 2003, American journal of respiratory cell and molecular biology.

[73]  M. Aubier,et al.  Airway structural alterations selectively associated with severe asthma. , 2003, American journal of respiratory and critical care medicine.

[74]  T. Harris,et al.  Impact of extracellular matrix and strain on proliferation of bovine airway smooth muscle , 2003, Clinical and experimental pharmacology & physiology.

[75]  William W Busse,et al.  Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial , 2003, The Lancet.

[76]  D. Hyde,et al.  The effect of house dust mite aeroallergen and air pollutant exposures during infancy. , 2003, Chest.

[77]  J. McConville,et al.  What evidence implicates airway smooth muscle in the cause of BHR? , 2003, Clinical reviews in allergy & immunology.

[78]  S. Holgate,et al.  Airway remodeling in asthma: new insights. , 2003, The Journal of allergy and clinical immunology.

[79]  H. Windom,et al.  Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. , 2003, The Journal of allergy and clinical immunology.

[80]  P. Howarth,et al.  Pharmacotherapy and airway remodelling in asthma? , 2003, Thorax.

[81]  Jeffrey M Drazen,et al.  Mechanical stress triggers selective release of fibrotic mediators from bronchial epithelium. , 2003, American journal of respiratory cell and molecular biology.

[82]  Jun Zou,et al.  Human ADAM33: protein maturation and localization. , 2003, Biochemical and biophysical research communications.

[83]  L. Boulet,et al.  Correlation between airway responsiveness and proteoglycan production by bronchial fibroblasts from normal and asthmatic subjects. , 2002, The international journal of biochemistry & cell biology.

[84]  P. Thomas,et al.  Effects of inhaled tumour necrosis factor alpha in subjects with mild asthma , 2002, Thorax.

[85]  P. Howarth,et al.  Asthmatic bronchial epithelium is more susceptible to oxidant-induced apoptosis. , 2002, American journal of respiratory cell and molecular biology.

[86]  Steuart Rorke,et al.  Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness , 2002, Nature.

[87]  Susan J Wilson,et al.  Cooperative Effects of Th2 Cytokines and Allergen on Normal and Asthmatic Bronchial Epithelial Cells1 , 2002, The Journal of Immunology.

[88]  A. Woodcock,et al.  Specific airway resistance in 3-year-old children: a prospective cohort study , 2002, The Lancet.

[89]  I. Adcock,et al.  p38 Mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: role in steroid-insensitive asthma. , 2002, The Journal of allergy and clinical immunology.

[90]  K. J. Macleod,et al.  Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma , 2002, Thorax.

[91]  P. Gibson,et al.  Neutrophil degranulation and cell lysis is associated with clinical severity in virus-induced asthma , 2002, European Respiratory Journal.

[92]  R. Pauwels,et al.  Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. , 2002, American journal of respiratory and critical care medicine.

[93]  D. Johns,et al.  Reduced airway distensibility, fixed airflow limitation, and airway wall remodeling in asthma. , 2001, American journal of respiratory and critical care medicine.

[94]  J. Cidlowski,et al.  Proinflammatory cytokines regulate human glucocorticoid receptor gene expression and lead to the accumulation of the dominant negative β isoform: A mechanism for the generation of glucocorticoid resistance , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[95]  P. Thomas.  Tumour necrosis factor‐α: The role of this multifunctional cytokine in asthma , 2001 .

[96]  W. Busse,et al.  Pathophysiology of severe asthma. , 2000, The Journal of allergy and clinical immunology.

[97]  M. Aldrich,et al.  Modulation of allergic inflammation in mice deficient in TNF receptors. , 2000, American journal of physiology. Lung cellular and molecular physiology.

[98]  N Franklin Adkinson,et al.  Long-term effects of budesonide or nedocromil in children with asthma. , 2000, The New England journal of medicine.

[99]  J. Spinelli,et al.  Polymorphisms in the IL4, IL4RA, and FCERIB genes and asthma severity. , 2000, The Journal of allergy and clinical immunology.

[100]  D. Johns,et al.  Airway distensibility in healthy and asthmatic subjects: effect of lung volume history. , 2000, Journal of applied physiology.

[101]  H. Bisgaard.  Long‐acting β2‐agonists in management of childhood asthma: A critical review of the literature , 2000 .

[102]  Britton,et al.  Association between − 308 tumour necrosis factor promoter polymorphism and bronchial hyperreactivity in asthma , 1999, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[103]  J. Lafitte,et al.  Increased glucocorticoid receptor beta in airway cells of glucocorticoid-insensitive asthma. , 1999, American journal of respiratory and critical care medicine.

[104]  V. Plaza,et al.  Costs of asthma according to the degree of severity. , 1998, The European respiratory journal.

[105]  J. Westwick,et al.  Airway inflammation induced by recombinant guinea pig tumor necrosis factor-alpha. , 1997, The American journal of physiology.

[106]  R. Djukanović,et al.  The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics. , 1997, The Journal of clinical investigation.

[107]  S. Holgate,et al.  Tumour necrosis factor alpha: a polcnlial mediator of asthma , 1995, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[108]  D. Yates,et al.  Tumor necrosis factor-alpha increases airway responsiveness and sputum neutrophilia in normal human subjects. , 1995, American journal of respiratory and critical care medicine.

[109]  Melinda Fitzgerald,et al.  Immunol. Cell Biol. , 1995 .

[110]  M. Hibbert,et al.  Outcome of childhood asthma in mid-adult life , 1994, BMJ.

[111]  P. Howarth,et al.  Interleukin-4, -5, and -6 and tumor necrosis factor-alpha in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. , 1994, American journal of respiratory cell and molecular biology.

[112]  R. Pauwels,et al.  Tumor necrosis factor causes bronchial hyperresponsiveness in rats. , 1992, The American review of respiratory disease.

[113]  P. Howarth,et al.  Myofibroblasts and subepithelial fibrosis in bronchial asthma. , 1990, American journal of respiratory cell and molecular biology.

[114]  S. Holgate,et al.  SUBEPITHELIAL FIBROSIS IN THE BRONCHI OF ASTHMATICS , 1989, The Lancet.

[115]  A. Cats,et al.  HL-A 27 AND ANKYLOSING SPONDYLITIS , 1975, The Lancet.